Bui Lecture.pdf

More documents

Recommendations

Info

Recombinase activating gene-deficient mice lack T, NK-T, and B cells. Shankaran et al., Nature 2001 Partially immune deficient mice develop a higher incidence of MCA-induced fibrosarcomas. Methods: Mice with different genetic deficiencies were injected subcutaneously with 3’methylcholanthrene and tumor incidence was assessed.
Shankaran et al., Nature 2001 Mice with partial immune deficiencies developed a higher incidence of spontaneous tumors. Methods: Mice were sacrificed at the indicated ages. Some were sacrificed at young ages due to “sickness”. Autopsies were performed and slides were reviewed by 3 pathologists.
Page 1 and 2: Tumor Immunology Jack Bui, MD, PhD
Page 4 and 5: Tumor immunology = the study of wha
Page 6 and 7: Immune cells function to eliminate
Page 8 and 9: Figure 15.12d The Biology of Cancer
Page 10 and 11: The birth of tumor immunosurveillan
Page 12: Paradigm shift : Cancers are opport
Page 18 and 19: The presence of tumor specific T ce
Page 20 and 21: Evidence for tumor immunosurveillan
Page 22 and 23: Shown is survival in ovarian cancer
Page 24: Endogenous T Cell Responses to Anti
Page 28 and 29: Goals 1. Present evidence that the
Page 30 and 31: Shankaran et al., Nature 2001 WT tu
Page 32 and 33: Cancer immunoediting: regressor tum
Page 35 and 36: Evidence for equilibrium • Human
Page 37 and 38: Melanoma complicating treatment wit
Page 39 and 40: Implications of equilibrium state
Page 41 and 42: Inflammation and Cancer: “Cancers
Page 43 and 44: Evidence for inflammation induced c
Page 45 and 46: Deletion of the NF-kB activator IKK
Page 47 and 48: Goals 1. Present evidence that the
Page 49 and 50: Evidence for Cancer Immunoediting:
Page 51 and 52: Normal cell Not recognized Induced-
Page 53 and 54: Gasser et al., DNA damage induces N
Page 55 and 56: Evidence for p53’s role in activa
Page 57 and 58: Corollary to Cancer Immunoediting:
Page 59 and 60: Passenger mutations leading to neo-
Page 61 and 62: Oncogene-driven models of cancer ca
Page 63 and 64:
Goals for this hour 1. Present evid
Page 65 and 66:
What cells/molecules promote vs inh
Page 67 and 68:
Immune therapy of melanoma • IL-2
Page 69:
Peripheral blood mononuclear cells
Page 74 and 75:
An example of immunotherapy
Page 76 and 77:
The presence of tumor specific T ce
Page 78:
Can we remove immune suppression?
Page 81 and 82:
Cancer immunoediting describes the
Page 83:
Some major unanswered questions •
show all

Bui Lecture.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?